Biotech SF
San Francisco Bay Area biotech stories.
Monday, January 31, 2011
Onyx multiple myeloma drug wins FDA fast-track status
UCSF nabs $20M gift from Ray and Dagmar Dolby for stem cell building
Douglas Rosenberg invests $3.5M toward Alzheimer's drug development at Buck Institute
Friday, January 28, 2011
BiPar breast cancer drug fails late-stage trial
Genentech's Rituxan wins FDA approval for advanced follicular lymphoma
Fluidigm prices IPO at $13.50 to $15 per share
Success with Genentech cancer drug Tarceva could end study early
Bionovo to raise $30M for R&D
UCSF to hire more San Francisco residents for hospital project
Portola Pharmaceuticals targets antidote to blood thinners
Thursday, January 27, 2011
Plexxikon starts Phase I trial of rheumatoid arthritis drug
$26.3M Eye Institute at Stanford named for VC giant Brook Byers and wife
Wednesday, January 26, 2011
FDA warns Genentech about Boniva ad with Sally Field
The plane truth: Elan execs take flight in face of layoffs
Tuesday, January 25, 2011
Report: Elan cuts 130 jobs, mainly in South SF, as execs take private jet
FDA wants more info on Gilead-Tibotec HIV drug combo
Codexis signs deal with Japan's Dainippon Sumitomo Pharma
Abaxis inks $30 million supply deal with Becton Dickinson
Monday, January 24, 2011
Nektar nets $220M from stock sale
Portola Pharma names 1st head of R&D
AcelRx Pharmaceuticals prices $81 million IPO
Friday, January 21, 2011
UCSF harvesting Big Pharma deals
Genomic Health hiring 50-100, expanding to 3rd building
Genomic Health pedals way to growth
California stem cell agency CIRM taps Amgen exec for new R&D post
Transcept awakens bid for sleeping pill approval
Venture investing way up in '10, modest increase in biotech
Corcept Therapeutics to sell $39M in stock
Wednesday, January 19, 2011
View from personalized medicine confab
Gordon & Rees starts life sciences practice
Nektar Therapeutics to sell 19M shares
Tuesday, January 18, 2011
Plexxikon, Roche melanoma drug improves survival
Protagonist Therapeutics, Ironwood Pharma sign peptide drug deal
Amgen to sell Fremont campus to Boehringer Ingelheim
Nektar Therapeutics plans stock sale
Alexza shares plummet after FDA setback
Genentech fires back at FDA over Avastin breast cancer rejection
Monday, January 17, 2011
Calif. AG leads battle against Bayer, 'reverse payments'
UCSF opening $15.5 million high-tech learning center
Friday, January 14, 2011
We are the world: Bay Area remains center of biotech
Melanoma drug, companion diagnostic marry Plexxikon, Roche Molecular Diagnostics
Index Ventures opening Bay Area office
Medtronic completes $800M acquisition of Ardian
In autism's storm: 2 champions stand firm in light of discredited doctor
Biotechs fight proposed building code in South S.F.
Wednesday, January 12, 2011
FibroGen launches mid-stage IPF drug trial
SRI International lands $17.4M in NIH deals
Codexis inks enzyme supply deal with DSM Pharm
UCSF, Sanofi-Aventis ink research, intern deal
Tuesday, January 11, 2011
Dynavax fills late-stage hepatitis vaccine trial
NextWave Pharmaceuticals raises $45M
Fast facts from J.P Morgan's 1st day
Monday, January 10, 2011
Bayer, UCSF ink master deal, but few details
Sangamo gives layoffs the zinc finger
OncoMed starts early test of solid tumor cancer drug
What's up at the J.P. Morgan conference — so far
Exelixis cancer drug wins 'orphan' tag
InterMune to start new IPF drug trial
JP Morgan Healthcare Conference: And they're off …
Friday, January 7, 2011
IPierian wants closer ties to 'father' of induced pluripotent stem cells Yamanaka
23andMe snags another $9M in funding
Executive Profile: iPierian CEO Michael Venuti
StemCells lines up $10M stock financing
UCSF, University of Michigan, Cleveland Clinic artificial kidney could knock out dialysis
Avastin, Esbriet drug approvals: Go figure
Pfizer, Sutro cut peptide drug research deal
Thursday, January 6, 2011
J.P. Morgan Healthcare Conference tops 2010 numbers
InterMune IPF drug strategy pays off
Affymax names new CEO, director
Genentech, Plexxikon ink sales deal
Denmark's Symphogen raises $130 million
Wednesday, January 5, 2011
FDA OKs expanded use of Genentech rheumatoid arthritis drug Actemra
Tuesday, January 4, 2011
Med device company PneumRx raises $33M
Boston Scientific buys remainder of Sadra Medical for $193M
Genentech licenses NY biotech's potential antibacterial compounds
Xoma gets flexibility in Servier deal, must deliver
Xoma snags up to $505M, including $35M upfront, for anti-inflammation/diabetes drug
Monday, January 3, 2011
New biotech conference crowds J.P. Morgan Week schedule
Saturday, January 1, 2011
Biotech in '11: Life science firms dive into great unknown
‹
›
Home
View web version